Zacks Research Has Optimistic View of VolitionRx Q4 Earnings

VolitionRx Limited (NYSE:VNRX) – Investment analysts at Zacks Research increased their Q4 2025 earnings estimates for shares of VolitionRx in a research report issued to clients and investors on Monday, March 9th. Zacks Research analyst S. Ralston now expects that the company will post earnings of ($0.04) per share for the quarter, up from their previous estimate of ($0.05). The consensus estimate for VolitionRx’s current full-year earnings is ($0.28) per share.

Other analysts have also recently issued research reports about the stock. Maxim Group cut shares of VolitionRx from a “buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price target on shares of VolitionRx in a research report on Wednesday, January 21st. Finally, HC Wainwright decreased their price objective on VolitionRx from $2.50 to $1.50 and set a “buy” rating on the stock in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $2.50.

VolitionRx Trading Up 1.3%

VolitionRx stock opened at $0.20 on Wednesday. The company has a 50-day moving average price of $0.25 and a 200 day moving average price of $0.38. VolitionRx has a 12-month low of $0.17 and a 12-month high of $0.94. The stock has a market cap of $27.48 million, a P/E ratio of -0.56 and a beta of 1.33.

Institutional Investors Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC boosted its position in shares of VolitionRx by 10.4% during the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock worth $6,367,000 after buying an additional 887,351 shares during the period. Lagoda Investment Management L.P. raised its holdings in shares of VolitionRx by 6.7% in the 3rd quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock valued at $8,476,000 after buying an additional 782,000 shares during the period. Citadel Advisors LLC raised its holdings in shares of VolitionRx by 70.1% in the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after buying an additional 135,775 shares during the period. Squarepoint Ops LLC acquired a new position in VolitionRx during the 4th quarter worth about $34,000. Finally, Jane Street Group LLC acquired a new position in VolitionRx during the 4th quarter worth about $28,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx NV is a multi-national in vitro diagnostics company focused on the development and commercialization of novel blood-based tests for the detection and monitoring of cancer and other diseases. The company’s proprietary Nucleosomics® technology leverages epigenetic and structural changes in nucleosomes—fragments of DNA wrapped around histone proteins—to identify disease-specific biomarkers in blood samples. VolitionRx’s primary goal is to offer simple, minimally invasive tests that facilitate early detection and improve patient outcomes.

VolitionRx’s product pipeline centers on the Nu.Q® family of immunoassays, which are designed to measure concentrations and modifications of circulating nucleosomes.